IDL Biotech AB takes a first step in introducing the rapid test for bladder cancer, UBC® Rapid, in the USA | IDL Biotech
IDL Biotech

CLOSE MENU

Articles

Bladder cancer

July 2019

IDL Biotech AB takes a first step in introducing the rapid test for bladder cancer, UBC® Rapid, in the USA

IDL Biotech has submitted supporting documents to the US FDA (Food and Drug Administration) to be able to obtain future approval of UBC® Rapid, the company's rapid test for bladder cancer.

Read the press release here (in swedish)

Meta analysis on TUBEX

Achieving accurate laboratory diagnosis of typhoid fever: a review and meta-analysis of TUBEX® TF clinical performance.

IDL signs distribution agreement in Uganda

IDL has signed a new distribution agreement in Uganda

IDL Biotech

Skip this intro